약제 내성 감시(AMR 대응) 시장 규모 : 솔루션별, 용도별, 최종 용도별 예측(2024-2032년)

Antimicrobial Resistance Surveillance Market size is projected to expand at 5.8% CAGR from 2024 to 2032 driven by the collaborative efforts among healthcare organizations, research institutions, and government bodies.

Increasing partnerships are fostering innovations in surveillance technologies, enabling the development of advanced tools for detecting and tracking resistant pathogens. For instance, in June 2023, several researchers at the Public Health Agency of Canada's National Microbiology Laboratory (NML) investigated the prevalence of antimicrobial resistance in Canada. Recognizing the need for a network that could capture data from across the nation, the NML created the Antimicrobial Resistance Network, or AMRNet, a lab-based monitoring system to collect data from bacterial and fungal samples tested for AMR in clinical and veterinary labs. Such collaborative initiatives pool resources, expertise, and data to enhance surveillance capabilities, leading to more effective strategies for antimicrobial resistance control, thereby augmenting the market outlook.

The overall industry is segmented into solution, application, end-use, and region.

In terms of solution, the antimicrobial resistance surveillance market from the diagnostic software segment is anticipated to witness 6.3% growth rate from 2024-2032. Advanced software solutions for antimicrobial resistance surveillance offer real-time monitoring, data analysis, and trend identification, aiding healthcare facilities in effective decision-making and infection control measures. They also provide rapid identification of resistant pathogens for enabling timely interventions and treatment strategies. Moreover, the integration of AI and ML algorithms enhances the accuracy and efficiency of surveillance systems, further adding to the segment growth.

Based on application, the antimicrobial resistance surveillance industry from the public health surveillance segment generated considerable revenue in 2023 and is estimated to depict a 6.1% CAGR between 2024 and 2032. Public health agencies worldwide rely on advanced surveillance systems to monitor and track the spread of antimicrobial resistance. Enhanced surveillance enables timely interventions, policy developments, and targeted interventions to combat antimicrobial resistance on a broader scale. With the increasing focus on preventing the spread of resistant pathogens and improving patient outcomes, the demand for robust public health surveillance solutions will rise.

Regionally, the Asia Pacific antimicrobial resistance surveillance industry is set to exhibit 6.3% CAGR during 2024-2032. The large and diverse population coupled with the rising healthcare expenditure are fueling the demand for effective surveillance solutions in the region. There are several government initiatives aimed at controlling infectious diseases and improving healthcare infrastructure. Additionally, the increasing prevalence of antimicrobial-resistant pathogens is driving the adoption of advanced surveillance technologies, thereby augmenting the regional industry outlook.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast calculations
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of antimicrobial resistance
    • 3.2.1.2 Increasing prevalence of infectious diseases
    • 3.2.1.3 Rising awareness and screening programs
    • 3.2.1.4 Advancements in diagnostic technologies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost associated with the procedures
    • 3.2.2.2 Lack of standardized protocols
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Solution, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Diagnostic kits
• 5.3 Diagnostic systems
• 5.4 Diagnostic software
• 5.5 Services

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Public health surveillance
• 6.3 Laboratory surveillance
• 6.4 Clinical diagnostics
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Clinics
• 7.4 Research & academic institutes
• 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 Accelerate Diagnostics, Inc.
• 9.3 Becton, Dickinson and Company (BD)
• 9.4 Biomereiux SA
• 9.5 Bruker Corporation
• 9.6 Himedia Laboratories Pvt. Ltd.
• 9.7 Opgen Inc.
• 9.8 Danaher Corporation
• 9.9 Luminex Corporation
• 9.10 Merck & Co., Inc.
• 9.11 Thermo Fisher Scientific Inc.